Results 161 to 170 of about 5,151 (200)
Some of the next articles are maybe not open access.
Epoetin Alfa Versus Darbepoetin Alfa in Chemotherapy-Related Anemia
Annals of Pharmacotherapy, 2006Objective: To review and compare the data concerning the clinical activity of epoetin alfa versus darbepoetin alfa when administered to patients with cancer who are experiencing treatment-related anemia. Data Sources: English-language publications from the MEDLINE database (1990–June 2005), published articles, and meeting abstracts were reviewed. Study
Robert J, Cersosimo, Daniel R, Jacobson
openaire +2 more sources
BioDrugs, 2005
Darbepoetin alfa (Aranesp), Nespo) is an amino acid substituted analog of human erythropoietin (EPO) that promotes erythrocyte survival, proliferation, and differentiation. Approved in Europe and the US for the treatment of anemia associated with chronic kidney disease (CKD), it is characterized by delayed clearance and a more prolonged elimination ...
Dean M, Robinson, Stephanie E, Easthope
openaire +2 more sources
Darbepoetin alfa (Aranesp), Nespo) is an amino acid substituted analog of human erythropoietin (EPO) that promotes erythrocyte survival, proliferation, and differentiation. Approved in Europe and the US for the treatment of anemia associated with chronic kidney disease (CKD), it is characterized by delayed clearance and a more prolonged elimination ...
Dean M, Robinson, Stephanie E, Easthope
openaire +2 more sources
Current opinion in investigational drugs (London, England : 2000), 2002
Amgen has launched darbepoetin alfa, synthetic recombinant novel erythropoiesis stimulating protein (NESP), for the treatment of anemia associated with renal disease. The drug was approved by the European Commission in June 2001, under the tradename Aranesp, for the treatment of anemia in chronic kidney failure including patients on and not yet on ...
F, Locatelli, L D, Vecchio
openaire +1 more source
Amgen has launched darbepoetin alfa, synthetic recombinant novel erythropoiesis stimulating protein (NESP), for the treatment of anemia associated with renal disease. The drug was approved by the European Commission in June 2001, under the tradename Aranesp, for the treatment of anemia in chronic kidney failure including patients on and not yet on ...
F, Locatelli, L D, Vecchio
openaire +1 more source